WithdrawnPhase 2

Tazemetostat for the Treatment of Moderate to Severe COVID-19 Infection

Stopped: FDA recommendation cited safety issues

0Started 2022-01

Plain-language summary

The purpose of this study is to assess the safety and efficacy of repurposing tazemetostat for the treatment of Acute Respiratory Distress Syndrome (ARDS) or Systemic Cytokine Release Syndrome (SCRS) in COVID-19 patients.

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study. * Male or female, aged 18-85 * Diagnosed with q-PCR confirmed infection with SARS-Cov-2 virus and admitted to the hospital. * Receiving non-invasive respiratory support through a nasal cannula or a face mask. * Ability to take oral medication and be willing to adhere to the tazemetostat regimen. Exclusion Criteria: * Unable to take PO medication. * Need for intubation or ECMO. * Pregnancy or lactation * Known allergic reactions to tazemetostat. * Active malignancy (not in remission). * Treatment with another investigational drug.

What they're measuring

Length of hospital stay

Timeframe: Up to one year from date of randomization

Trial details

NCT IDNCT05018975

SponsorLoma Linda University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-09-21

View on ClinicalTrials.gov More COVID-19 Acute Respiratory Distress Syndrome trials